5244122026-04-012026-06-305244122026-06-305244122026-04-012026-06-30in-capmkt:OtherExpenses1Member5244122026-04-012026-06-30in-capmkt:OtherExpenses2Member5244122026-04-012026-06-30in-capmkt:OtherExpenses3Member5244122026-06-30

Statement1

5244122026-04-012026-06-30

Statement1

5244122026-06-30

StatementDynamic1I1

Statement1

iso4217:INRxbrli:pureiso4217:INRxbrli:shares

524412

AAREYDRUGS

NOTLISTED

INE198H01019

Aarey Drugs and Pharmaceuticals limited

Main Board

Equity

2026-04-01

2027-03-31

2026-08-14

2026-08-07

INR

Lakhs

Quarterly

First quarter

Single segment

DRUGS AND PHARMACEUTICALS

2026-08-14

17:00:00

2026-08-14

19:00:00

Not applicable

true

false

2026-04-01

2026-06-30

Unaudited

Standalone

446255000

17150000

463405000

434776000

-13235000

1634000

16744000

8502000

9828000

458249000

5156000

3000000

-8081000

-5081000

10237000

284543000

0.36

General Administrative expense

1795000

Selling and Distribution Expense

3462000

other expense

4571000

Preferential Issues

2025-05-23

79750000

2026-06-30

false

Mira Ghatalia

Chief Financial Officer

Mumbai

2026-08-14

The Company, as a part of its financial strategy, proposes to offer, issue and allot Convertible Warrants to its Promoter/Non-Promoter/Promoter group member on preferential basis, for infusing additional funds in the Company which may be employed in the business of the Company and/or may be used to augment the funding needs for re-structuring/settlement of liabilities/debts and/or such other appropriate arrangements and/or understanding with Bankers and/or other Creditors and/or investment in technology and/or for general corporate purposes which shall enhance the business of the Company and for any other purpose as may be decided and approved by the Board.

319000000

The Company had allotted 50,00,000 Convertible Warrants on May 23, 2025, at an issue price of Rs. 63.80 per warrant, aggregating to Rs. 3,190.00 lakhs. In accordance with the SEBI (ICDR) Regulations, 25% of the consideration amounting to Rs. 797.50 lakhs was received at the time of allotment and was utilized for the stated objects. The balance 75% consideration amounting to Rs. 2,392.50 lakhs is receivable upon exercise/conversion of the warrants within the prescribed period. <br /> The aforesaid details were reported in the Statement of Deviation and Variation for the year ended March 31, 2026. During the quarter ended June 30, 2026, no further funds were received towards the balance consideration of the Convertible Warrants. Accordingly, there was no fresh fund receipt or utilization during the quarter and the Statement of Deviation and Variation for the quarter ended June 30, 2026 has been filed as Nil. <br />